In addition, the population variations in circulating levels of ALT accounted for by these variants are very low, ranging from 0.20 to 0.36%.[39]–[41] Larger more adequately powered GWAS may help unravel new variants with larger effects on ALT levels, enabling assessments of any causal association of ALT levels with risk of MetS. This evidence concerns the gene GPT and metabolic syndrome.